临床试验设计,生物标志物和终点在代谢和与酒精有关的肝病
Luis Antonio Diaz1,2, Maja Thiele3,4, Alexandre Louvet5,6
1MASLD Research Center, Division of Gastroenterology and Hepatology, University of California San Diego, San Diego, CA, USA.
Nature reviews. Gastroenterology & hepatology
|September 27, 2025
概括
代谢和与酒精有关的肝病 (MetALD) 需要特定的临床试验标准,包括代谢功能障碍和酒精暴露. 非侵入性生物标志物和适应性设计对于高效的MetALD药物开发至关重要.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 临床试验设计 临床试验设计
- 代谢性疾病研究研究
背景情况:
- 代谢性和与酒精有关的肝病 (MetALD) 是脂肪性肝病中的一个新实体.
- 它涉及心脏代谢风险因素和酒精消费,这给研究带来了挑战.
- 了解MetALD的流行病学和病理生理学是关键.
研究的目的:
- 为MetALD.概述最佳的临床试验设计策略.
- 解决患者选择和结果测量的挑战.
- 为了加速MetALD.的药物开发.
主要方法:
- 建议纳入标准:代谢功能障碍 (≥2特征) 和经过验证的酒精摄入量 (3-6个月).
- 突出非侵入性终点:成像,血清生物标志物和定量酒精测量.
- 建议适应性试验设计和根据代谢风险对患者进行分层.
主要成果:
- 非侵入性方法为组织学提供可复制和以患者为中心的替代方案.
- 生物标志物和定量措施提高了试验的可行性和精度.
- 分层和适应性设计提高了通用性.
结论:
- 精细的诊断标准和验证的非侵入性终点对于MetALD试验至关重要.
- 提高试验效率将促进新的干预措施.
- 需要进一步的研究来解决患者选择和结果评估中的不确定性.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
185
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
185
Bioavailability Study Design: Healthy Subjects Versus Patients
144
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
144
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
214
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
214
Clinical Trials
10.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.1K
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
182
Body:Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
182


